Fusion Pharmaceuticals Inc. Active Patents
2 granted patents the USPTO still lists as patented, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2019-12-04: Application 16619432; Invention ACTINIUM-225 AND CHECKPOINT INHIBITOR COMBINATION THERAPY; Applicant Fusion Pharmaceuticals Inc.; Status Patented Case.
- 2017-08-15: Application 15678027; Invention IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF; Applicant Fusion Pharmaceuticals Inc.; Status Patented Case.
| Filed | Application | Invention | Applicant | Status | Granted | Patent | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-12-04 | 16619432 | ACTINIUM-225 AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. | Patented Case | 2022-09-20 | 11446401 | US20220088230A1 | Eric Steven BURAK Julie METCALF Natalie GRINSHTEIN Meiduo HU John Fitzmaurice VALLIANT | Canada Canada Canada Canada Canada | STOICA, ELLY GERALD |
| 2017-08-15 | 15678027 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | Fusion Pharmaceuticals Inc. | Patented Case | 2018-10-09 | 10093741 | Eric Steven BURAK John Richard FORBES Matthew David Burr MORAN Ryan Wayne SIMMS John Fitzmaurice VALLIANT | Canada Canada Canada Canada Canada | JONES, DAMERON LEVEST |